Lynthera

Lynthera Corporation is a biotechnology research company based in Lancaster, Pennsylvania, that specializes in the development of drug delivery and formulation technologies for ocular therapeutics. The company has created a novel platform for the controlled, sustained release of medications directly to the eye, most notably a drug-eluting contact lens (DDCL). This technology utilizes nanotechnology and charged boundary layers to overcome the limitations of traditional topical eye drops, which are often restricted by natural ocular defensive mechanisms and inconsistent dosing. By allowing for precise, sustained accumulation of therapeutics on the corneal surface, the platform aims to improve treatment efficacy and patient adherence.

This technology is primarily being developed to treat common eye conditions, including glaucoma, dry eye, and myopia control. The company has secured multiple federal grants, including funding from the National Institutes of Health (NIH), to support its research and development pipeline. These efforts include projects focused on delivering immunomodulators like cyclosporine A and exploring other therapeutic applications. Lynthera continues to advance its platform toward clinical evaluation, working to establish a new paradigm in eye care that could provide safer and more effective solutions for patients suffering from persistent inflammatory and degenerative eye diseases.